ClinicalTrials.gg
TerminatedNCT02314247Updated Jan 26, 2023Results posted

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

A Phase 2 interventional study of Selinexor in Peripheral T-cell Lymphoma (PTCL) and Cutaneous T-cell Lymphoma (CTCL), sponsored by Karyopharm Therapeutics Inc. Terminated at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-26.

Sponsored by Karyopharm Therapeutics Inc · Phase 2, Interventional, and Treatment

Why this study was terminated
Due to enrollment challenges

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Lymphoma, T-Cell, Peripheral with a site in Australia — 3 open to participants now, 4 under way, 1 of them phase 3. Lymphoma, T-Cell, Peripheral · Australia.

Enrollment
13th of 16
16 · median 120
Started
2015
with 1 other
Phase 2
6 of 16
none open now
Registered
6th of 16
by date
Lead sponsor
1 of 16
Karyopharm Therapeutics Inc

Among the 16 studies in Lymphoma, T-Cell, Peripheral with a site in Australia, this one is the 13th largest by enrollment, is one of 2 that started in 2015, is one of 6 in phase 2, and was the 6th registered.

Lymphoma, T-Cell, Peripheral

372 studies on the registry are indexed under Lymphoma, T-Cell, Peripheral; 110 are open to participants now.

Browse Lymphoma, T-Cell, Peripheral studies →

Open to participants now

3 of the 16 studies in Lymphoma, T-Cell, Peripheral with a site in Australia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 76 Lymphoma, T-Cell, Peripheral studies recruiting now, 30 (39%) set no upper age limit and 38 (50%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Lymphoma, T-Cell, Peripheral with a site in Australia, or all of them as a file.
02

Study summary

This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.

Approximately 60 patients with relapsed or refractory PTCL or CTCL who meet the eligibility criteria and have none of the exclusion criteria will be enrolled to receive selinexor until either disease progression or intolerance has occurred.

Read the detailed description

This is a single-arm, multi-center, open-label phase 2 study of the SINE™ compound selinexor given orally to patients with relapsed or refractory PTCL or CTCL.

Approximately 60 patients with relapsed or refractory PTCL or CTCL who meet the eligibility criteria and have none of the exclusion criteria will be enrolled to receive selinexor until either disease progression or intolerance has occurred.

Enrolled patients will be given selinexor as an oral fixed 60 mg dose (equivalent to \~35 mg/m²) on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (total 8 doses per cycle).

There is no maximum treatment duration. Patients will receive supportive therapy to mitigate selinexor side effects, as well as best supportive care (BSC).

Patients enrolled under Protocol Versions \<3.0 were to receive selinexor orally, at a fixed dose of 60 mg (equivalent to \~35 mg/m²) on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (total of 6 doses per cycle). Selinexor was not taken during Week 4.

For all patients enrolled in this study (regardless of the protocol version) who continued onto Cycle 3 and forward, the dose was to be increased by 20 mg to 80 mg (administered on Days 1 and 3 of Weeks 1-4), only after consultation with the Sponsor's Medical Monitor.

03

Conditions studied

  • Peripheral T-cell Lymphoma (PTCL)
  • Cutaneous T-cell Lymphoma (CTCL)

Keywords

  • PTCL
  • CTCL
  • Peripheral T-cell Lymphoma
  • Cutaneous T-cell Lymphoma
  • Karyopharm
  • KPT-330
  • Selinexor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • performance status of ≤2.
  • disease to at least one prior systemic regimen.
  • : according to International Working Group (IWG) guidelines for all patients with PTCL and according to CTCL Response in Skin consensus criteria for all patients with CTCL.
  • Objective, documented evidence of disease progression on study entry.

Exclusion criteria

Exclusion Criteria:

  • Known active central nervous system (CNS) lymphoma.
  • Active after stem cell transplantation. At least 4 months must have elapsed since completion of allogeneic stem cell transplantation.
  • Unable to swallow tablets or malabsorption syndrome, disease significantly affecting gastrointestinal function.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Selinexor

    60 mg dose (equivalent to \~35 mg/m²)

    Drug: Selinexor

Interventions

  • 20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle (Protocol V.3.0). 20 mg oral tablets: 60 mg dose on Days 1 and 3 of Weeks 1-3 of each 4-week cycle (Protocol V.\<3.0). Number of Cycles: up to 12 but there is no maximal duration for treatment.

    Also known as: KPT-330

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    Overall Response (OR) = Complete Response (CR) + Partial Response (PR). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment. Progression was defined as the first occurrence of progressive disease (PD) per the revised response criteria. Clinical disease progression in the absence of formal criteria for PD must be documented by a physician.

    Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.

  2. Best Overall Response: Complete Response (CR)

    Patients who achieved CR (disappearance of all detectable evidence of disease). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

    Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.

  3. Best Overall Response: Partial Response (PR)

    Patients whose best overall response to study treatment was PR (regression of measurable disease and no new sites). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

    Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.

  4. Best Overall Response: Stable Disease (SD)

    Patients whose best overall response to study treatment was SD (failure to attain criteria needed for CR or PR, or to meet criteria for PD). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

    Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.

  5. Best Overall Response: Progressive Disease (PD)

    Patients whose best overall response to study treatment was PD. Progression was defined as the first occurrence of progressive disease (PD). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment. Clinical disease progression in the absence of formal criteria for PD must be documented by a physician.

    Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.

  6. Best Overall Response: Not Evaluable (NE)

    Patients who could not be assessed quantitatively for disease response for any reason.

    Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.

Secondary outcomes

  1. Duration of Stable Disease, Including Patients With Partial Response

    Duration of time from the date of start of study treatment to the date of disease progression. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

    Time frame: Date of start of study treatment to date of progression. Patients without documented PD are censored on date of last radiologic assessment.

  2. Disease Control Rate (DCR)

    Percentage of patients who have CR, PR, or SD lasting ≥ 8 weeks. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

    Time frame: Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.

  3. Progression Free Survival (PFS)

    Duration of time from start of study treatment to date of disease progression or death from any cause.

    Time frame: Study treatment start date to date of disease progression or date of death. Patients without documented PD are censored on date of last radiologic assessment.

07

Results

Posted Aug 20, 2018
Limitations and caveats
Due to unexpectedly slow recruitment, the Sponsor decided to terminate the study after 16 patients had been enrolled. The small study population limits the evaluation of both efficacy and safety of selinexor in patients with PTCL or CTCL.

Participant flow

Participant flow — Overall Study
MilestoneSelinexor (PTCL)Selinexor (CTCL)Selinexor (CTCL) 8 Doses/Cycle
Started961
Completed000
Not completed961
Withdrew: Adverse event210
Withdrew: Withdrawal by subject131
Withdrew: Progression of disease620

Outcome measures

PrimaryOverall Response Rate (ORR)

Overall Response (OR) = Complete Response (CR) + Partial Response (PR). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment. Progression was defined as the first occurrence of progressive disease (PD) per the revised response criteria. Clinical disease progression in the absence of formal criteria for PD must be documented by a physician.

Time frame:
Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR)
Percentage of participantsSelinexor (PTCL)Selinexor (CTCL)
Overall Response Rate (ORR)11.1 (1.2 to 36.8)14.3 (1.5 to 45.3)
PrimaryBest Overall Response: Complete Response (CR)

Patients who achieved CR (disappearance of all detectable evidence of disease). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

Time frame:
Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Reported as:
Count of participants · Participants
Best Overall Response: Complete Response (CR)
ParticipantsSelinexor (PTCL)Selinexor (CTCL)
Best Overall Response: Complete Response (CR)00
PrimaryBest Overall Response: Partial Response (PR)

Patients whose best overall response to study treatment was PR (regression of measurable disease and no new sites). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

Time frame:
Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Reported as:
Count of participants · Participants
Best Overall Response: Partial Response (PR)
ParticipantsSelinexor (PTCL)Selinexor (CTCL)
Best Overall Response: Partial Response (PR)11
PrimaryBest Overall Response: Stable Disease (SD)

Patients whose best overall response to study treatment was SD (failure to attain criteria needed for CR or PR, or to meet criteria for PD). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

Time frame:
Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Reported as:
Count of participants · Participants
Best Overall Response: Stable Disease (SD)
ParticipantsSelinexor (PTCL)Selinexor (CTCL)
Best Overall Response: Stable Disease (SD)24
PrimaryBest Overall Response: Progressive Disease (PD)

Patients whose best overall response to study treatment was PD. Progression was defined as the first occurrence of progressive disease (PD). Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment. Clinical disease progression in the absence of formal criteria for PD must be documented by a physician.

Time frame:
Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Reported as:
Count of participants · Participants
Best Overall Response: Progressive Disease (PD)
ParticipantsSelinexor (PTCL)Selinexor (CTCL)
Best Overall Response: Progressive Disease (PD)20
PrimaryBest Overall Response: Not Evaluable (NE)

Patients who could not be assessed quantitatively for disease response for any reason.

Time frame:
Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Reported as:
Count of participants · Participants
Best Overall Response: Not Evaluable (NE)
ParticipantsSelinexor (PTCL)Selinexor (CTCL)
Best Overall Response: Not Evaluable (NE)42
SecondaryDuration of Stable Disease, Including Patients With Partial Response

Duration of time from the date of start of study treatment to the date of disease progression. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

Time frame:
Date of start of study treatment to date of progression. Patients without documented PD are censored on date of last radiologic assessment.
Reported as:
Median · Days
Duration of Stable Disease, Including Patients With Partial Response
DaysSelinexor (PTCL)Selinexor (CTCL)
Duration of Stable Disease, Including Patients With Partial Response120.5 (111.0 to 130.0)112.0 (85.0 to 225.0)
SecondaryDisease Control Rate (DCR)

Percentage of patients who have CR, PR, or SD lasting ≥ 8 weeks. Objective disease response assessment in PTCL patients was made according to the revised response criteria based on the International Working Group (IWG) guidelines for malignant lymphoma (Cheson, 2007). Objective disease response assessment in CTCL patients was assessed according to the revised CTCL Consensus Response Criteria (Olsen, 2011) using physical examination, including the Modified Severity Weighted Assessment Tool (mSWAT) for skin assessment. CTCL Global Response Score was used as a secondary efficacy assessment.

Time frame:
Disease response was assessed at screening and every 8 weeks (patients with PTCL); or at Cycle 1 Day 1 and every 4 weeks (patients with CTCL), until disease progression.
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR)
Percentage of participantsSelinexor (PTCL)Selinexor (CTCL)
Disease Control Rate (DCR)33.3 (12.9 to 59.9)71.4 (40.4 to 92.1)
SecondaryProgression Free Survival (PFS)

Duration of time from start of study treatment to date of disease progression or death from any cause.

Time frame:
Study treatment start date to date of disease progression or date of death. Patients without documented PD are censored on date of last radiologic assessment.
Reported as:
Median · Days
Progression Free Survival (PFS)
DaysSelinexor (PTCL)Selinexor (CTCL)
Progression Free Survival (PFS)111.0 (41.0 to 130.0)112.0 (85.0 to 225.0)

Adverse events

Collected over Day of onset after the first dose of study treatment through 30 days following the last dose of study treatment.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selinexor (PTCL)3/9 (33.3%)8/9 (88.9%)9/9 (100%)
Selinexor (CTCL)1/7 (14.3%)1/7 (14.3%)7/7 (100%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventSelinexor (PTCL)Selinexor (CTCL)
ThrombocytopeniaBlood and lymphatic system disorders2/90/7
FallInjury, poisoning and procedural complications0/91/7
AnemiaBlood and lymphatic system disorders1/90/7
Febrile NeutropeniaBlood and lymphatic system disorders1/90/7
PneumoniaInfections and infestations1/90/7
Wound Infection StaphylococcalInfections and infestations1/90/7
AphasiaNervous system disorders1/90/7
LethargyNervous system disorders1/90/7
DyspneaRespiratory, thoracic and mediastinal disorders1/90/7
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders1/90/7
Most frequent other events
Showing 10 of 41
Most frequent other events
EventSelinexor (PTCL)Selinexor (CTCL)
NauseaGastrointestinal disorders5/95/7
Decreased AppetiteMetabolism and nutrition disorders2/95/7
FatigueGeneral disorders4/95/7
ConstipationGastrointestinal disorders1/94/7
DiarrheaGastrointestinal disorders2/91/7
VomitingGastrointestinal disorders2/91/7
AnaemiaBlood and lymphatic system disorders2/90/7
ThrombocytopeniaBlood and lymphatic system disorders2/90/7
NeutropeniaBlood and lymphatic system disorders2/90/7
PruritusSkin and subcutaneous tissue disorders2/91/7

Baseline characteristics

Age, Continuous
Age, Continuous(years)Selinexor (PTCL)Selinexor (CTCL)Total
Median65 (51 to 83)74 (59 to 84)69 (51 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Selinexor (PTCL)Selinexor (CTCL)Total
Female224
Male7512
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selinexor (PTCL)Selinexor (CTCL)Total
Hispanic or Latino000
Not Hispanic or Latino8715
Unknown or Not Reported101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selinexor (PTCL)Selinexor (CTCL)Total
American Indian or Alaska Native000
Asian112
Native Hawaiian or Other Pacific Islander000
Black or African American000
White8614
More than one race000
Unknown or Not Reported000
08

Study locations

5 sites
  • Concord Repatriation General Hospital (CRGH)
    Concord, New South Wales 2139, Australia
  • Royal North Shore Hospital
    St. Leonards, New South Wales 2139, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Cabrini Hospital
    Malvern, Victoria, Australia
  • National Cancer Centre
    Singapore, 169610, Singapore
09

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2015, a primary completion of Jan 2016 and a completion of Feb 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 3, 2014
First posted
Dec 11, 2014
Start
Feb 2015
Primary completionActual
Jan 2016
CompletionActual
Feb 2016
Results first posted
Aug 20, 2018
Last update
Jan 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02314247
Responsible party
Sponsor
First posted
Dec 11, 2014
Start date
Feb 2015
Primary completion
Jan 2016
Completion
Feb 2016
Results posted
Aug 20, 2018
Last update
Jan 26, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selinexor

Start the discussion